Titre
New approaches for temozolomide therapy: use in newly diagnosed glioma
Type
synthèse (review)
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Périodique
Auteur(s)
Stupp, R.
Auteure/Auteur
Newlands, E.
Auteure/Auteur
Liens vers les personnes
Liens vers les unités
ISSN
0093-7754
Statut éditorial
Publié
Date de publication
2001-08
Volume
28
Numéro
4 Suppl 13
Première page
19
Dernière page/numéro d’article
23
Notes
Journal Article
Review --- Old month value: Aug
Review --- Old month value: Aug
Résumé
Temozolomide is a novel oral alkylating agent that has been approved for the treatment of patients with refractory malignant glioma. Treatment with temozolomide is now being explored in patients with newly diagnosed malignant glioma in several ongoing clinical trials, and alternative treatment schedules are being evaluated. A schedule of continuous daily treatment with temozolomide for 6 or 7 weeks has been developed and determined to be safe, effective, and well tolerated. When temozolomide was continuously given along with a standard course of radiation therapy for 6 or 7 weeks, followed by adjuvant treatment with temozolomide, promising preliminary results were seen in patients with malignant gliomas.
Sujets
PID Serval
serval:BIB_B8017927CC8F
PMID
Date de création
2008-01-28T07:39:08.806Z
Date de création dans IRIS
2025-05-21T04:51:10Z